Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Nonrandomized, Dose-Escalation and Tumor-Expansion Phase 1 Study to Evaluate the Safety and Tolerability of INCSHR01210 (Formerly SHR-1210) in Subjects With Advanced Solid Tumors

NCT02492789 is registered in ClinicalTrials.gov with Atridia Pty Ltd. as lead sponsor.

NCT NCT02492789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02492789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Nonrandomized, Dose-Escalation and Tumor-Expansion Phase 1 Study to Evaluate the Safety and Tolerability of INCSHR01210 (Formerly SHR-1210) in Subjects With Advanced Solid Tumors
Lead sponsor
Atridia Pty Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2015
Completion date
July 5, 2019
Enrollment
49 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors and hematologic malignancy